Chimeric: Media Thread, page-985

With the imminent release of prelim data for the first 3 patients in CHMs CDH17 CART trial, here are some pointers on what “good looks like”:

- No dose limiting toxicities;
- Evidence of tumour infiltration by the CART. This may include “pseudo profession” whereby the tumour temporarily, increases in size;
- Reduction in the size of tumour(s);
- Durability of the response ie. progression free survival;

note, given this data will relate to the first cohort of patients on the trial who are on the lowest dose, any early signs of efficacy will be super encouraging!